Sudan University of Science and Technology
College of Graduate Studies

Immunohistochemical Detection of Cyclin D1 in Ovarian Cancers
Among Sudanese Women

الكشف النسيجي الكيميائي المناعي عن السايكلين د1 في اورام المبيض لدى النساء السودانيات

A dissertation submitted in partial fulfillment for the requirements of M.Sc.
Degree in Medical Laboratory Science (Histopathology and Cytology)

By:
Mohanad Mohammed Mosbah Alhamss

B.Sc. in Medical Laboratory Science (Histopathology and Cytology)
(University of Khartoum 2013)

Supervisor:
Dr. Abu Elgasim Abass Awad Elkareem

2017
بسم الله الرحمن الرحيم

قال تعالى:

وَيُسَالُونَكَ عَنِ الْرَّوحِ قُلِّ الْرَّوحُ مِنْ أَمْرِ رَبِّي وَمَا أُوْتِيْنِي مِنَ الْعِلْمِ إِلَّا قَلِيلًا

صدق الله العظيم

سورة الإسراء الآية (85)
I
Dedication

To my father

To my mother

To my sisters

To my sons

To my family

To all my teachers

To all my colleagues and friends

With love and respect.
Acknowledgment

I’m grateful to Allah for the care, insight, peaceful and pity in my life. I would like to express my profound thanks to my supervisor, Dr. Abu ElgasimAbass, for his patience, guidance, unlimited assistance, encouragement and sustained interest throughout the course of this work.

I wish to extend my warmest thanks to the staff of the histopathology and cytology department, college of medical laboratory science, Sudan university of science and technology for their continuous support and encouragement.

Finally, I would like to thanks everybody who imported to the successful realization of this research, as well as expressing my apology to these who I could not mention personally one by one.
Abstract

This an analytical retrospective case control hospital based study was conducted in Radiation and Isotope Center Khartoum (RICK), and national public health laboratory during the period from August 2016 to April 2017. The study aimed to detect cyclin D1 expression in ovarian tumors using immunohistochemistry. Forty paraffin embedded blocks previously diagnosed as ovarian tumors were collected. Samples include 30 (75%) malignant tumors (including serous carcinoma in 14 (35%) samples, mucinous carcinoma in 3 (7.5%) samples, endometrioid carcinoma in 5 (12.5%) samples, clear cell carcinoma in 2 (5%) samples, adenocarcinoma in 4 (10%) samples, germ cell carcinoma in 2 (5%) samples) and 10 (25%) benign samples. The patient’s age ranged between 23 and 70 years with mean age of 46 years, most patients were more than 40 years representing 23 (57.5%) and the remaining 17 (42.5%) patients were less than 40 years. One section of 3 micrometer thickness was cut from each paraffin block by rotary microtome and stained by immunohistochemical method (indirect streptavidin-biotin immunoperoxidase technique) for detection of cyclin D1. Data collected from patients files and results obtained were analyzed using SPSS computer program. Immunohistochemical expression of cyclin D1 was revealed positive expression in 18/30 samples and negative result in 12/30 samples in malignant tumors, while all benign tumors gave negative result for cyclin D1 (0/10), with significant statistical association between cyclin D1 expression and histopathological diagnosis of ovarian tumor (P. value = 0.001). This study concludes that cyclin D1 expression is associated with malignant forms of ovarian tumors.
ال연구 التحليلي المستشفى

أجريت هذه الدراسة التحليلية التراجعية المستشفى في مركز العلاج بالإضافة والطب النووي في ولاية الخرطوم والمعمل القومي للصحة العامة خلال الفترة من أغسطس 2016 إلي أبريل 2017. هدفت الدراسة للكشف عن سايكلين 1 في أورام المبيض باستخدام كيمياء الأنسجة المناعية.

جتمت أربعون عينة مسمورة بسمع البارفين. من عينات مرضى تم تشخيصهم مسبقا بورام المبيض. تتكون العينات من 30 (75%) عينة لأورام خبيثة، تضمنت سرطان المصل في 14 (35%) من العينات، وسرطان الخلايا الصافية في 2 (5%) عينة، سرطان الخلايا الغدي في 4 (10%) عينة، سرطان الخلايا الجرثومية في 2 (5%) عينة و10 (25%) عينات لأورام حميدة. تراوحت اعمار المرضى بين 23-70 سنة ومتوسط العمر 46 سنة. أغلب المرضى 23 (57.5%) كانت أعمارهم أكثر من 40 سنة وجثمة المرضى 17 (42.5%) كانت اعمارهم أقل من 40 سنة.

تم قطع مقطع واحد من كل عينة بسمك 3µm بواسطة جهاز المشراح الدوار. تم صب الصبغات بواسطة كيمياء الأنسجة المناعية (تقنية تقنية البيوتين المناعي غير المباشر) للكشف عن سايكلين 1. تم جمع البيانات من ملفات المرضى. تم استخدام برنامج الحزمة الإحصائية للعلوم الاجتماعية SPSS لتحليل البيانات.

أظهرت الدراسة عن التعبير المناعي للسايكلين D1 أنها موجبة الظهور في 18/30 عينة وسالبة الظهور في 12/30 عينة من عينات الأورام الخبيثة بينما كل عينات الأورام الحميدة الظهور نتائج سالبة للسايكلين D1 مع وجود علاقة إحصائية بين السايكلين D1 ونوع الورم (القيمة الاحتمالية=0.001).

خلصت الدراسة إلى أن هناك علاقة بين افراز السايكلين D1 والأورام الخبيثة للمبيض.
List of contents

<table>
<thead>
<tr>
<th>Content</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>الابية</td>
<td>I</td>
</tr>
<tr>
<td>Dedication</td>
<td>II</td>
</tr>
<tr>
<td>Acknowledgement</td>
<td>III</td>
</tr>
<tr>
<td>Abstract (English)</td>
<td>IV</td>
</tr>
<tr>
<td>Abstract (Arabic)</td>
<td>V</td>
</tr>
<tr>
<td>List of contents</td>
<td>VI</td>
</tr>
<tr>
<td>List of tables</td>
<td>VIII</td>
</tr>
<tr>
<td>List of photographs</td>
<td>IX</td>
</tr>
<tr>
<td><strong>Chapter one: Introduction</strong></td>
<td></td>
</tr>
<tr>
<td>1.1 Introduction</td>
<td>1</td>
</tr>
<tr>
<td>1.2 Objectives</td>
<td>2</td>
</tr>
<tr>
<td><strong>Chapter two: Literature review</strong></td>
<td></td>
</tr>
<tr>
<td>2.1 Scientific background</td>
<td>3</td>
</tr>
<tr>
<td>2.2 Structure of the ovary</td>
<td>3</td>
</tr>
<tr>
<td>2.2.1 Location and description of ovary</td>
<td>3</td>
</tr>
<tr>
<td>2.2.2 Histology and embryology of ovary</td>
<td>3</td>
</tr>
<tr>
<td>2.3.1 Disorders of the ovary (benign)</td>
<td>4</td>
</tr>
<tr>
<td>2.3.2 Disorder of the ovary (malignant)</td>
<td>5</td>
</tr>
<tr>
<td>2.4 Epidemiology of ovarian cancer</td>
<td>7</td>
</tr>
<tr>
<td>2.5 Risk factors of ovarian cancer</td>
<td>7</td>
</tr>
<tr>
<td>2.6 Diagnosis of ovarian cancer</td>
<td>8</td>
</tr>
<tr>
<td>2.7 Treatment of ovarian cancer</td>
<td>9</td>
</tr>
<tr>
<td>2.8 Cyclin D1 and its relation with ovarian cancer</td>
<td>10</td>
</tr>
<tr>
<td><strong>Chapter three: Materials and methods</strong></td>
<td></td>
</tr>
<tr>
<td>3.1 Materials</td>
<td>11</td>
</tr>
<tr>
<td>3.2 Methods</td>
<td>11</td>
</tr>
<tr>
<td>3.2.1 Study design</td>
<td>11</td>
</tr>
<tr>
<td>3.2.2 Study samples</td>
<td>11</td>
</tr>
<tr>
<td>3.2.3 Study area</td>
<td>11</td>
</tr>
<tr>
<td>3.2.4 Sample processing</td>
<td>11</td>
</tr>
<tr>
<td>3.2.5 Immunohistochemical staining</td>
<td>11</td>
</tr>
<tr>
<td>Chapter four: Results</td>
<td>13</td>
</tr>
<tr>
<td>-------------------------------</td>
<td>----</td>
</tr>
<tr>
<td>Results</td>
<td></td>
</tr>
<tr>
<td>Chapter five : Discussion</td>
<td>19</td>
</tr>
<tr>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>Chapter six : Conclusion and recommendation</td>
<td>20</td>
</tr>
<tr>
<td>6.1 Conclusion</td>
<td></td>
</tr>
<tr>
<td>6.2 Recommendations</td>
<td>20</td>
</tr>
<tr>
<td>References</td>
<td>21</td>
</tr>
<tr>
<td>Appendices 1</td>
<td>27</td>
</tr>
<tr>
<td>Appendices 2</td>
<td>28</td>
</tr>
</tbody>
</table>
## VII

### List of tables

<table>
<thead>
<tr>
<th>Table</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Table (4.1), Distribution of age group among the study population</td>
<td>14</td>
</tr>
<tr>
<td>Table (4.2), Distribution of histopathological diagnosis among the study population</td>
<td>15</td>
</tr>
<tr>
<td>Table (4.3), Relation between histopathological diagnosis and cyclin D1 expression</td>
<td>16</td>
</tr>
</tbody>
</table>
## List of photographs

<table>
<thead>
<tr>
<th>Photograph</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Photograph (4.1) Serous carcinoma of ovary shows positive expression of cyclin D1 (40×).</td>
<td>17</td>
</tr>
<tr>
<td>Photograph (4.2) Benign ovarian tumor shows negative expression of cyclin D1 (40×).</td>
<td>18</td>
</tr>
</tbody>
</table>
CHAPTER ONE

INTRODUCTION
Chapter one

Introduction

1.1 Introduction:

Ovarian cancer is one of the highly lethal malignancy of the female genital tract due to growth may occur for a long period of time without clinical symptoms and the absence of reliable screening tests in the early stages (Goff, et al. 2000).

Worldwide ovarian cancer is the fifth-leading cause of cancer-related deaths in women. It is estimated that in 2016, there will be more than 22,200 new cases of ovarian cancer and more than 14,200 deaths from ovarian cancer in the United States (Doubeni et al. 2016).

In Sudan, the incidence rate of the ovarian cancers in Khartoum Sudan during 2009 - 2010 (the specific rate = 8 per 100,000) (Saeed, et al. 2014).

Risk factors which increase a woman’s ovarian cancer include family history, age, childbirth menopause, genetics, previous gynecological problems and lifestyle (Permuth et al. 2009).

Methods of ovarian cancer diagnosis include a blood test, magnetic resonance imaging (MRI) or computerized tomography (CT) scan and ultrasound (Gubbels, et al. 2010).

The treatment for ovarian cancer depends on the grade and stage of the tumor at presentation. Treatment modalities include either cystectomy, or oophorectomy, salpingo-opectomy, hysterectomy, chemotherapy and radiotherapy (Nucci and Oliva, 2009).
Cyclin D1 is one of the cell cycle proteins, affects the proliferation of a cell. The expression of cyclin D1 might be responsible for progression and ultimately tumorigenesis of human ovarian cancer epithelial tissues (Wu, et al. 2009). Overexpression of cyclin D1 was also observed by Dhar et al. in 89% of 81 epithelial ovarian tumor sections in both borderline and invasive tumors. There was no association between protein overexpression and tumor stage or grade of differentiation. Furthermore, no correlation between cyclin D1 expression and clinical outcome was observed (Dhar, et al. 1999). The normal ovarian surface epithelium failed to stain with anticyclin D1. Positive immunostaining of cyclin D1 protein was observed in 10 (56%) of 18 ovarian tumors (Shigemasa, et al. 1999).

1.2 Objectives:

General objective:
To detect cyclin D1 expression in ovarian tumor tissue immunohistochemically and its correlation with histopathological diagnosis.
CHAPTER TWO

LITERATURE REVIEW
Chapter two

Literature review

2.1 Scientific background:
Ovarian cancer is the second most common gynecologic malignancy and the most common cause of gynecologic cancer death in the United States. The majority of ovarian malignancies (95%) are derived from epithelial cells; the remainder arise from other ovarian cell types (germ cell tumors, sex cord-stromal tumors) (Markman, et al. 2001). Ovarian cancer is difficult to detect, especially, in the early stages. This is partly due to the fact that these two small, almond shaped organs are deep within the abdominal cavity, one on each side of the uterus (Wang, et al. 2005).

2.2 Structure of the ovary:
2.2.1 Location and description:
Each ovary is an almond-shaped organ, measuring 4×2 cm, and is attached to the back of the broad ligament by the mesovarium. The ovary usually lies in the ovarian fossa, which is bounded by the external iliac vessels above and by the internal iliac vessels and ureter behind. The ovary is surrounded by a thin fibrous capsule, the tunica albuginea, which is covered by a layer of cuboidal cell called germinal epithelium. Before puberty, the ovary is smooth, but after puberty it becomes scarred due to successive corpora lutea degeneration. After the menopause the ovary becomes shrunken (Snell, 1995).

2.2.2 Histology and embryology:
The ovary consists of a cortical region and a medullary area. The cortical region consists of follicles (oocytes) that are embedded in the stroma. The medullary region contains a rich vascular bed within a loose connective tissue (Junqnerira and Carneiro, 2005).

2.3 Disorder of the ovary:
2.3.1 Benign disorder:

2.3.1.1 Cystadenofibroma:
Cystadenofibroma is a subset of epithelial ovarian neoplasms that are usually benign. A lesion with a solid portion that exhibits intense contrast enhancement is the prominent feature of cystadenofibroma that mimics malignancy. The presence of rims, plaques, or nodules that have low signal intensity on T2-weighted images and that range from 2 mm to 4 cm in a multiloculated cystic ovarian mass can suggest the diagnosis. The low-signal-intensity foci correspond to intratumoral regions of dense fibrous tissue (Outwater, et al. 1997).

2.3.1.2 Serous cystadenoma:
These arise from the cuboidal epithelium covering the ovary. This type of benign ovarian tumour is the most common diagnosed in women aged over 40 years, and its presence gives the scarred ovarian surface a smooth appearance (Karlan, et al. 2012).

2.3.1.3 Mature cystic teratoma:
Mature cystic teratomas are benign germ cell tumors. They usually have the highest sensitivity and specificity for a specific diagnosis with ultrasound as they generally have rather typical features. They are cystic and unilocular in the majority of cases, with mixed echogenicity representing the different components of fat, bone and fluid (Ameye, et al. 2012).

2.3.1.4 Mucinous cystadenoma:
Mucinous cysts are classically thin walled, large and unilateral. They consist of internal thin-walled locules containing mucin which appears as fluid with low level echogenicity. In general neither serous nor mucinous cystadenomas are associated with significant vascularity (Karlan, et al. 2012).

**2.3.2 Malignant disorder:**

**2.3.2.1 Serous carcinomas:**

Serous carcinomas represent the vast majority of primary malignant ovarian tumors (75%–80%) and are composed of columnar cells with cilia. These tumors are subdivided into high-grade and low-grade serous carcinomas (Malpica, et al. 2004).

**2.3.2.1.1 High-grade serous carcinoma (HGSC):**

These are the most common ovarian carcinomas and most patients present with advanced stage disease (~80%); tumors confined to the ovary at diagnosis are distinctly uncommon (<10%). Microscopically, HGSC show papillary and solid growth with slit-like glandular lumens. The tumor cells are typically of intermediate size, with scattered bizarre mononuclear giant cells exhibiting prominent nucleoli in contrast to LGSCs, these tumors show more than threefold variation in nuclear size. Also, mitotic activity greater than 12/10 high-power microscopic fields (HPFs) favors a diagnosis of HGSC (Prat, 2012).

**2.3.2.1.2 Low-grade serous carcinoma (LGSC):**

LGSC is less common, representing 10%-15% of serous carcinomas and <5% of all ovarian carcinomas. This carcinoma is associated with a serous borderline tumor or represents the recurrent lesion observed after a diagnosis of borderline serous tumor. This tumor is composed of non-hierarchical papillae or micropapillae without nuclear atypia and with less than 12 mitoses per 10 high-
power fields. Patients with these slow growing tumors exhibit a 10-year survival rate of 50% (median overall survival, 82 months) and a relative insensitivity to chemotherapy (Jones, et al. 2012).

2.3.2.2 Endometrioid carcinomas:
Endometrioid carcinomas account for 10% of all ovarian carcinomas and are generally unilateral solid masses with a smooth outer surface. These tumors are composed of glands resembling endometrial epithelium and may be associated (23%-42%) with ovarian or pelvic endometriosis. These tumors exhibit CK7-, PAX8-, and hormone (estrogen and progesterone) receptor-positive as well as WT1- and CK20-negative staining; these classifications aid in the distinction from serous and colonic carcinomas, respectively. These tumors are graded into three grades according to the International Federation of Gynecology and Obstetrics (FIGO) system, which is based on the presence of solid areas and the degree of nuclear atypia. Grade 3 tumors tend to harbor TP53 mutations and may be difficult to distinguish from HGSCs (Geyer, et al. 2009).

2.3.2.3 Clear-cell cancers:
Clear-cell cancers account for ~5% of ovarian cancers, although the incidence varies worldwide. The prognosis for stage 1 clear-cell cancers is relatively good. However, advanced stage clear-cell cancers have a worse prognosis than serous ovarian cancers as the tumours tend to be resistant to the standard chemotherapeutical agents used in ovarian cancer. Clear-cell cancers are also strongly associated with endometriosis and a significant proportion carries ARID1A mutations (Wiegand, et al. 2010).

2.3.2.4 Mucinous carcinomas:
Primary mucinous carcinomas are classified as intestinal tumors (containing goblet cells) and comprise only 2%-3% of ovarian carcinomas. These tumors are unilateral, stage I (75%-80%), large (18-22 cm), and multicystic tumors filled with
mucus. They often contain solid areas. Histologically, they are composed of cysts and glands of variable size, with a confluent pattern and back-to-back glands. Complex papillary architecture is also observed. The cells are tall, columnar, and stratified with basophilic cytoplasm containing mucin. Invasive mucinous carcinomas are sub classified as expansile and infiltrative pattern types (Prat, 2012).

2.4 Epidemiology:
The incidence of ovarian cancer varies widely among different populations worldwide with the highest rates reported in Scandinavia, Eastern Europe, Canada, and Africa. The lowest rates have been reported from Asia, with the exception of Japan. The rate of ovarian cancer in Iran has been reported as 3.9 per 100,000 (Haem, et al, 2015). In Sudan, according to reports derived (2009-2010) from the National Cancer Registry for Khartoum State alone, ovarian cancer was the fourthmost common cancer in women, with an estimated incidence rate of 188 per 100,000 population, a gender specific rate of 8.0 per 100,000 population, and an age standardized rate (ASR) of 7.0 per 100,000 population (Abuidris, et al, 2016).

2.5 Risk factors:
The risk factors of ovarian cancer include:

2.5.1 Age:
The risk of ovarian cancer increases with age. Women over 50 year have the highest risk of developing ovarian cancer (Roett and Evans, 2009).

2.5.2 Family history:
If a woman’s mother or sister has had ovarian, breast, or uterine cancer she is at greater risk of developing ovarian cancer (Permuth, et al, 2009).

2.5.3 Infertility:
Infertile women and those with a condition called endometriosis and those who use postmenopausal estrogen replacement therapy are at increased risk for ovarian cancer (Pearce, *et al.* 2012).

**2.5.4 Genetics:**
Certain genetic traits can also increase the risk of developing ovarian cancer. Such as women with mutations in the BRCA1 or BRCA2 genes (1 in every 500 women) have a 23-54% risk of developing ovarian cancer (Roett and Evans, 2009).

**2.5.5 Diabetes:**
Developing ovarian cancers has a risk of 20 – 55% higher in diabetic women comparing to non-diabetic ones and slight higher in insulin dependent patient than non-dependent ones (Starup, *et al.* 2013).

**2.5.6 Obesity/overweight:**
Being obese or overweight increases the risk of developing ovarian cancers, and increases the rate of death from these cancers (Cibula, *et al.* 2011).

**2.5.7 HRT (Hormone replacement therapy):**
Slightly increases a women's risk of developing ovarian cancer. Experts say that the risk increases the longer the HRT continues, and returns to normal as soon as treatment stops, being obese or overweight increases the risk of developing many cancers (Permuth, *et al.* 2009).

**2.5.8 Smoking:**
Current smoking has also been associated with decreased risk of clear cell ovarian tumors, however no association was observed with serous and endometrioid tumors; and doubled the risk of mucinous ovarian cancers (Jordan, *et al.* 2006).

**2.6 Diagnosis of ovarian cancer:**
Diagnosis starts with taking history and making physical examination including pelvis, this may be guided by plenty of imaging methods; for instance, CT-scan,
transvaginal ultrasound and MRI. Moreover, biochemical markers should be included, for they help greatly in differential diagnosis and follow up of the disease such as Ca125 which on the other hand showed low value at diagnosis of early stage ovarian cancer. Other markers may include B-HCG, alpha-fetoprotein, and lactate dehydrogenase. Apart from physical examination methods, biological specimens should be adopted for laboratory investigations, this necessitates collecting aspirated fluid from abdominal cavity to check for malignant cells. Then for a definitive diagnosis, the surgical procedure is important to inspect the abdomen. This can be by an open procedure (laparotomy incision) or key surgery (Laparoscopy) to enable suspicious areas to be biopsied and then sent for microscopically examination (Chobanian and Dietrich, 2008).

2.7 Treatment of ovarian cancer:

2.7.1 Surgery:
Surgery is used to remove as much of the tumour as possible. This is known as debulking surgery or cytoreduction. Patients most commonly have both ovaries removed (bilateral oophorectomy) and a hysterectomy (removal of the uterus). In young women who wish to remain fertile, only the affected ovary is removed and the uterus is left in place (Gubbels, et al. 2010).

2.7.2 Chemotherapy:
Chemotherapy after surgery is referred to as ‘front-line’ or ‘first-line’ treatment and involves a combination of a platinum and taxane-based chemotherapy (usually carboplatin and paclitaxel). Patients with advanced ovarian cancer who aren’t initially able to undergo surgery due to large ascites or invasive tumours can be treated with chemotherapy before being considered for surgery (neoadjuvant treatment) (Hennessy, et al. 2009).

2.7.3 Radiation:
Radiation is most often used for palliative purposes and for localized persistent disease after chemotherapy (Roett and Evans, 2009).

2.8 Cyclin D1 and its relation with ovarian cancer:
Cyclin D1 overexpression may play an important role in the tumorigenesis of epithelial ovarian tumors (Shigemasa, et al., 1999).
Dharet et al. who used a mouse monoclonal antibody, described overexpression of the cyclin D1 protein in up to 89% of the cancers examined. In their study, the protein expression was spotted in the cytoplasm of the tumor cells in 59% of cases; thus, only 30% of the tumors examined displayed nuclear expression of cyclin D1. Cyclin D1 was overexpressed in both borderline and invasive tumors. There was no association between protein overexpression and tumour stage and differentiation. Furthermore, no correlation between cyclin D1 expression and clinical outcome was observed. However, in tumours overexpressing cyclin D1, the proportion displaying exclusively cytoplasmic localization of protein was higher in those with serous compared with non-serous histology (Dhar, et al., 1999). According to some authors detected a significant correlation between cyclin D1 expression and malignant potential of the serous ovarian tumors. Moreover, cyclin D1 expression was positively correlated with the advanced stage and tumor grade. The exact impact on tumor biology and the use of cyclin D1 expression in clinical practice remain to be elucidated (Turan, et al., 2014).
Lin and Yu reported that cyclin D1 expression in malignant tumors and borderline
tumors was significantly higher than that in benign tumors (P < 0.005) and normal ovarian tissues (P < 0.005). However, there were no significant differences between borderline tumors and malignant tumors (P > 0.05), and benign tumors and normal tissue (P = 0.237). Overall, cyclin D1 expression was increased from benign to borderline to malignant tumors (Lin and Yu, 2011).

CHAPTER THREE

MATERIALS AND METHODS
Chapter three
Materials and methods

3.1 Materials:
Archived tissue blocks of ovarian tumors were selected for this study.

3.2 Methods:

3.2.1 Study design:
This is hospital based analytical retrospective case control study aimed to detect cyclin D1 expression in ovarian tumors.

3.2.2 Study samples:
Tissue blocks obtained from thirty samples previously diagnosed as malignant ovarian tissue and ten samples which previously diagnosed as benign tumor were collected. Patient’s data (age, histopathological diagnosis) were obtained from patients files.

3.2.3 Study area:
This study was held in Radiation and Isotope Center Khartoum (RICK) and national public health laboratory during period from August 2016 to April 2017.

3.2.4 Sample processing:
Sections of 3μm thickness was cut by rotary microtome, mounted in positively charged glass slides and put at 60°C oven for 30 minutes.
3.2.5 Immunohistochemical staining:

Immunohistochemical staining was carried out using indirect streptavidin-biotin immune peroxidase technique. Tissue sections (3µm) were deparaffinized in xylene and rehydrated in graded alcohol (100%, 90%, 70%, 50%) and water two minutes for each, then slides were incubated for 10 minutes in 0.3% hydrogen peroxide to block endogenous peroxidase activity. Antigen retrieval was performed by using PT link water path with citrate buffer (pH 6.8). The slides then were treated with anti cyclin D1 primary antibody for 30 minutes, then section were incubated in biotinylated secondary antibody for 15 minutes then washed in phosphate buffer saline (pH7.4), incubated in streptavidin-HRP (horseradish peroxidase) for 15 minutes, washed in phosphate buffer saline (pH7.4), incubated in diaminobenzidine tetra hydrochloride (DAB) substrate solution, washed in running tap water. Then counterstained in Mayer’s hematoxylin stain for 1 minute. Dehydrated, cleared and mounted in DPX mounting media (Bancroft, et al. 2013).

3.2.6 Data analysis:

Data analysis was done using SPSS 20 computer program. Frequencies mean and Chi-square test values were calculated.

3.2.7 Result interpretation:

All quality control measures were adopted; positive and negative control slides were used during immunohistochemical staining. Detection of more than 5 cells with cytoplasm per one field considered as positive result.

3.2.8 Ethical consideration:

Samples were collected after taking ethical acceptance from hospital administration.
CHAPTER FOUR

RESULTS
Chapter Four

4. Results

The age of study population range between 23 and 70 years with mean age of 46 years, and standard deviation 13.8.

Most patient’s were more than 40 years representing 23 (57.5%) and the remaining 17 (42.5%) were less than 40 years as indicated in table (4.1).

The study includes forty samples, 30 (75%) samples were malignant and 10 (25%) samples were benign. The diagnosis of malignant samples include serous carcinoma in 14 (35%) samples, mucinous carcinoma in 3 (7.5%) samples, endometrioid carcinoma in 5 (12.5%) samples, clear cell carcinoma in 2 (5%) samples, adenocarcinoma in 4 (10%) samples, and germ cell carcinoma in 2 (5%) samples as indicated in table (4.2).

Cyclin D1 positive expression was found (18/30) in malignant samples, while (12/30) samples showed negative expression, while all benign samples (0/10) showed negative expression for cyclin D1. This result showed significant association (P. value = 0.001) as indicated in table (4.3).
Table (4.1): Distribution of age group among the study population:

<table>
<thead>
<tr>
<th>Age group</th>
<th>Frequency</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Less than 40 years</td>
<td>17</td>
<td>42.5%</td>
</tr>
<tr>
<td>More than 40 years</td>
<td>23</td>
<td>57.5%</td>
</tr>
<tr>
<td>Total</td>
<td>40</td>
<td>100%</td>
</tr>
</tbody>
</table>
Table (4.2): Distribution of histopathological diagnosis among the study population:

<table>
<thead>
<tr>
<th>Histopathological diagnosis</th>
<th>Type</th>
<th>Frequency</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Benign</td>
<td></td>
<td>10</td>
<td>25%</td>
</tr>
<tr>
<td>Malignant</td>
<td>Serous carcinoma</td>
<td>14</td>
<td>35%</td>
</tr>
<tr>
<td></td>
<td>Mucinous carcinoma</td>
<td>3</td>
<td>7.5%</td>
</tr>
<tr>
<td></td>
<td>Endometrioid carcinoma</td>
<td>5</td>
<td>12.5%</td>
</tr>
<tr>
<td></td>
<td>Clear cell carcinoma</td>
<td>2</td>
<td>5%</td>
</tr>
<tr>
<td></td>
<td>Adenocarcinoma</td>
<td>4</td>
<td>10%</td>
</tr>
<tr>
<td></td>
<td>Germ cell carcinoma</td>
<td>2</td>
<td>5%</td>
</tr>
<tr>
<td>Total</td>
<td></td>
<td>40</td>
<td>100%</td>
</tr>
</tbody>
</table>
Table (4.3): Relation between histopathological diagnosis of ovarian tumor and cyclin D1 expression:

<table>
<thead>
<tr>
<th>Histopathological diagnosis</th>
<th>Cyclin D1 expression</th>
<th>P. value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Positive</td>
<td>Negative</td>
</tr>
<tr>
<td>Benign</td>
<td>0 (0.0%)</td>
<td>10 (100%)</td>
</tr>
<tr>
<td>Malignant</td>
<td>18 (45%)</td>
<td>12 (30%)</td>
</tr>
<tr>
<td>Total</td>
<td>18 (45%)</td>
<td>22 (55%)</td>
</tr>
</tbody>
</table>
Photograph (4.1) Serous carcinoma of ovary show positive expression of cyclin D1 (40×).
Photograph (4.2) Benign ovarian tumor show negative expression of cyclin D1 (40×).
CHAPTER FIVE

DISCUSSION
Chapter Five

5. Discussion

The present study involves 40 cases of ovarian tumors, immunohistochemically stained for cyclin D1. Regarding the age group of patient’s, the study revealed that most patients were more than 40 years, indicating that older women are more susceptible to ovarian cancer. This result is compatible with Booth et al. (1989), they proved that there was a direct correlation between the age and ovarian cancer, and reported that late menopause and infertility increase the risk of ovarian cancer. Also agree with Abuidris et al. (2016), they reported that the incidence rate of ovarian cancer increased greatly in women aged 55 years or older.

The histopathological diagnosis of patients revealed that more frequent type of ovarian cancer was serous carcinoma, this result is compatible with Sarkar et al. (2015), they reported that (14 / 20) cases of malignant tumors of ovary were diagnosed as serous carcinoma. Also combatable with Ferrandina et al. (2005), they reported that (73 / 110) cases of malignant lesions of ovary were diagnosed as serous carcinoma. Also agree with Lin and Yu (2011), they reported that (21/30) of cases of ovary malignant lesions were diagnosed as serous carcinoma.

Regarding cyclin D1 expression the study found that (18/30) of malignant lesions showed positive expression and (12/30) showed negative expression, while all benign cases of ovarian lesion showed negative expression for cyclin D1. This relation showed significant association (P.valu=0.001). This result is compatible with Lin and Yu (2011), they reported that 90 %(27/30) of malignant lesions showed positive expression, and (2/10) of benign lesions of ovarian showed positive cyclin D1 expression. Also agree with Turan et al. (2014), they reported that 95.6 % (22/23) malignant lesions showed positive expression, and positive rate of cyclin D1 in benign ovarian lesions was 48 %(12/25).
CHAPTER SIX
CONCLUSION AND RECOMMENDATIONS
Chapter Six

Conclusion and Recommendations

6.1 Conclusion:

From this study we conclude that:

- The most common age of the ovarian cancer patients is more than 40 years.
- Most histological type of ovarian cancer is serous carcinoma.
- Cyclin D1 expression is associated with malignant forms of ovarian tumors.

6.2 Recommendations:

From this study we recommended that:

Further research should be done on expression of cyclin D1 in ovarian tumors tissue with large sample size.
References


Appendix 1:

Materials and instruments used for processing and staining of the specimens include:

Disposable gloves.
Rotary microtome.
Microtome knives.
Positively charged slides (Thermo).
Cover glasses.
Dry oven.
Water path (Dako water path).
Coplin jars.
Humidity chamber.
Ethanol (100%, 90 %, 70 %, 50 %).
Xylene.
Mayer`s haematoxylin.
Citrate buffer (pH6.8).
Phosphate buffer (PH7.4).
0.3 Hydrogen peroxidase.
Primary antibody (Cyclin D1).
Secondary antibody (biotinylated secondary antibody).
Streptavidin-HRP
Substrate chromogen (DAB).
DPX
Appendix 2:

FLEX
Monoclonal Rabbit
Anti-Human
Cyclin D1
Clone EP12
Ready-to-Use
(Dako Autostainer/Autostainer Plus)

English

Species

Rabbit

Code

K063

Intended use

For in vitro diagnostic use.

SYNOPSIS

This monoclonal antibody recognizes the human Cyclin D1 protein, which is component of the cyclin-dependent kinases CDK4 and CDK6. The antibody is intended for use in immunohistochemistry with DAKO Autostainer/Autostainer Plus instruments. Immunohistochemistry is useful for the identification of mantle cell lymphoma (MCL). The clinical interpretation of any staining or its absence should be confirmed by morphological studies using proper controls and should be evaluated within the context of the patient's clinical history and other diagnostic tests performed by a qualified pathologist.

Precautions

1. This product contains sodium azide (0.1%) as a preservative. Always add to water for use before preparing slides.

2. Use the antibody as directed. When using specific fixation methods, it is important to ensure the antibody is compatible with the method used.

3. Store on ice for up to 24 hours or at room temperature for up to 3 days. Do not freeze.

Staining procedure

1. Place a few drops of EnVision FLEX Peroxidase-Blocking Reagent (DAB2) on a glass slide and let it dry at room temperature.

2. Incubate the tissue section with EnVision FLEX Peroxidase-Blocking Reagent (DAB2) for 5 min at room temperature.

3. Wash the sections in EnVision FLEX Peroxidase-Washing Buffer (Code K8037) for 5 min at room temperature.

4. Incubate the tissue section with EnVision FLEX Peroxidase-Horse Radish Peroxidase (HRP) (Code K8067) for 5 min at room temperature.

5. Wash the sections in EnVision FLEX Peroxidase-Washing Buffer (Code K8037) for 5 min at room temperature.

6. Incubate the tissue section with EnVision FLEX Peroxidase-Horse Radish Peroxidase (HRP) (Code K8067) for 5 min at room temperature.

7. Wash the sections in EnVision FLEX Peroxidase-Washing Buffer (Code K8037) for 5 min at room temperature.

8. Incubate the tissue section with EnVision FLEX Peroxidase-Horse Radish Peroxidase (HRP) (Code K8067) for 5 min at room temperature.

9. Rinse in EnVision FLEX Peroxidase-Washing Buffer (Code K8037) for 5 min at room temperature.

10. Incubate the tissue section with EnVision FLEX Peroxidase-Horse Radish Peroxidase (HRP) (Code K8067) for 5 min at room temperature.

11. Rinse in EnVision FLEX Peroxidase-Washing Buffer (Code K8037) for 5 min at room temperature.

12. Counterslide with EnVision FLEX Hematoxylin (Code K8005) for 1 min at room temperature.

13. Rinse in water for 5 min at room temperature.

14. Mount slide with permanent mounting medium.

15. Incubate in diaminobenzidine (DAB) for 5 min at room temperature.

16. Mount slide with permanent mounting medium.